AcuVid™ aim is to make the world a safer place and allow economies to open and stay open by offering simple, low-cost antigen and antibody rapid screening test for COVID-19.
The World Health Organization sent a clear message to all countries in March 2021: test, test, and test… The more tests that are conducted, the easier it becomes to track the spread of the virus and reduce transmission.
COVID-19 Rapid Saliva Antigen Test
AcuVid™ COVID-19 Rapid Antigen Saliva Test aim is to make the world a safer place, allowing economies to re-open safely and stay open, while mitigating the spread of COVID-19 by infected and asymptomatic people. AcuVid™ Covid-19 Tests offer a simple, low-cost rapid screening solution for the immediate detection of the novel coronavirus (SAR-CoV-2) Wuhan strain, as well as other COVID-19 variants, such as the Brazilian P.1 and P.2 strain and the UK B.1.1.7 strain.
In March 2021, both the World Health Organization (WHO) and the US Centers for Disease Control (CDC) sent a clear message and guidance for all countries to conduct serial testing. Serial testing involves testing the same individual multiple times within a few days, and can increase chances of detecting asymptomatic infection that might not always show up with a single test. The more tests that are conducted, the easier it becomes to track the spread of the virus and reduce transmission.
Therma Bright’s white-labeled AcuVid™ COVID-19 Rapid Antibody Test is a simple pinprick antibody blood test (i.e. serology test) that uses a small amount of blood. The antibody test has a 96.6% sensitivity for detecting antibodies of SARS-CoV-2 in those individuals currently infected with the virus or who have previously been infected, but went undiagnosed or were unaware of their infection. It will also aid in determining antibodies generated by those who have received a COVID-19 vaccine.